Castle Biosciences completed the acquisition of Myriad myPath® Melanoma from Myriad Genetics for $32.5m.

Synopsis

Castle Biosciences, a biotechnology company, completed the acquisition of Myriad myPath® Melanoma, a laboratory offering the myPath Melanoma test, from Myriad Genetics, a genetic testing and precision medicine company, for $32.5m.

Principals

target

Myriad Mypath Melanoma

bidder

Castle Biosciences

Show Details & Financials

Did you work on this deal?

Claim Deal

Showcase your expertise to over 3 million dealmakers and industry leaders on Datasite.

Claim Deal

Market Context

MergerLinks - Castle Biosciences completed the acquisition of Myriad myPath® Melanoma from Myriad Genetics for $32.5m.